COVID-19: Yamasa supplies mRNA raw material: to Pfizer and Moderna

1-Me-Pseudouridine

COVID-19: Yamasa supplies mRNA raw material: to Pfizer and Moderna

-Yamasa’s “Pseudouridine” for corona vaccine-

Yamasa Soy Sauce Japan :

Yamasa Soy Sauce has a strong presence in the supply of the main raw material for the new coronavirus vaccine.

US Pfizer and Moderna:

US Pfizer, Moderna, etc.
A major overseas pharmaceutical company is developing a new vaccine,
We are paying attention to the technology of Yamasa soy sauce.

In fact, major overseas pharmaceutical companies purchase raw materials from Yamasa Soy Sauce.

Supply of “Pseudouridine”:

Founded in 1645, Yamasa Soy Sauce is headquartered in Chiba.

It supplies vaccine raw materials called “pseudouridine” to Pfizer and Moderna.

“Pseudouridine” is

It is indispensable for the important genetic substance “messenger RNA (mRNA)” of the new corona vaccine.

Hungarian researcher
Dr. Katalin Kariko

We focused on “uridine,” one of the substances that make up mRNA.

By replacing “uridine” with “pseudouridine”
Not recognized as foreign by the body’s immune system

It has been shown that it is easier to stay in the body.

Research on making umami ingredients:

Yamasa
Making soy sauce,

It has been going on for nearly 400 years.
Entered the pharmaceutical field in the 1970s by deriving research on making umami ingredients.

Export of “Pseudouridine” overseas:

Started exporting pseudouridine overseas from the 1980s.

In the past, it was mainly for research use and shipments were small.

Today, the situation has changed completely due to the corona sickness, and it has grown more than tens of times as much as before the corona.

Yomiuri Shimbun Online

https://www.yomiuri.co.jp/economy/20211013-OYT1T50086/

Materials used for mRNA synthesis

Yamasa
provides the materials used for synthesis of mRNA.

Yamasa
has been providing high quality Pseudouridine used for mRNA COVID-19 vaccines in commercial scale.

APIs

Yamasa manufactures small molecular active pharmaceutical ingredients (APIs) of nucleic acid related compounds.

Yamasa provides APIs for new drugs at all stage from R&D to commercial, and for generic drugs.

In addition to the listed products which are examples of APIs for generic drugs, we are manufacturing other APIs.

Product List | YAMASA CORPORATION Biochemicals Division

https://www.yamasa.com/biochem/en/product/#pro06

Yamasa Ramps Up API CMO Biz for Oligonucleotides, mRNA Drugs amid Changes in Modalities

PHARMA JAPAN

https://pj.jiho.jp/article/245027